| Company Name: |
LGM Pharma |
| Tel: |
1-(800)-881-8210 |
| Email: |
inquiries@lgmpharma.com |
| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
- Lificiguat
-
- $44.00
-
2026-05-26
- CAS:170632-47-0
- Purity: 99.74%
- Supply Ability: 10g
|
| Product Name: | YC-1 | | Synonyms: | 2-Furanmethanol, 5-[1-(phenylmethyl)-1H-indazol-3-yl]-;Nsc728165;(5-(1-Benzyl-1H-indazol-3-yl)furan-2-yl)Methanol;YC 1 (pharMaceutical);1-Benzyl-3-(5-hydroxymethylfur-2-yl)indazole;1-benzyl-3-(5-hydroxymethyl-furan-2-yl)indazole;Lificiguat(YC-1);5-[1-(PHENYLMETHYL)-1H-INDAZOL-3-YL]-2-FURANMETHANOL | | CAS: | 170632-47-0 | | MF: | C19H16N2O2 | | MW: | 304.34 | | EINECS: | | | Product Categories: | | | Mol File: | 170632-47-0.mol |  |
| Melting point | 110-112℃ | | Boiling point | 522.2±50.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMSO: 12 mg/mL | | pka | 13.83±0.10(Predicted) | | form | solid | | color | white | | Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months. | | InChI | 1S/C19H16N2O2/c22-13-15-10-11-18(23-15)19-16-8-4-5-9-17(16)21(20-19)12-14-6-2-1-3-7-14/h1-11,22H,12-13H2 | | InChIKey | OQQVFCKUDYMWGV-UHFFFAOYSA-N |
| WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| Description | YC-1 (170632-47-0) is a nitric oxide-independent activator of soluble guanylyl cyclase (sGC). Significantly elevates cGMP levels and inhibits collagen-stimulated aggregation of rabbit platelets (IC50= 14.6 μM).1Induces human endometrial cancer cell senescence via modulation of HIF1α activity.2Induces degradation of HIF1α.3Protects against glutamate-induced neuronal damage4and β-amyloid-induced toxicity in differentiated PC12 cells5. | | Uses | YC-1 has been used as a hypoxia-inducible factor 1α (HIF-1α) inhibitor:
- to reduce hypoxia induced Jagged1 expression in cardiomyocytes (CMs)
- to study its effect on progenitor expansion and CD34+ and side population (SP) cell phenotype and on the proliferation rate of cells with an ability to form long term colony forming units
- to study its effect on regulating sphingosine 1-phosphate (S1P) bound to albumin induced plasminogen activator inhibitor 1 (PAI-1) expression by activating Rho/ Rho-associated protein kinase (ROCK) pathway.
| | Definition | ChEBI: Lificiguat is a member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation. It has a role as an antineoplastic agent, a soluble guanylate cyclase activator, an apoptosis inducer, a platelet aggregation inhibitor and a vasodilator agent. It is a member of indazoles, a member of furans and an aromatic primary alcohol. | | General Description | A nitric oxide-independent, superoxide-sensitive activator of soluble guanylyl cyclase. Inhibits platelet adhesion to collagen and acts as an antithrombotic agent. Reported to reduce HIF-1α levels and xenograft growth. | | Biochem/physiol Actions | YC-1 activates soluble guanylyl cyclase and prevents platelet aggregation and vascular contraction. It has a potential to treat circulation disorders. YC-1 also has an ability to inhibit hypoxia-inducible factor 1α (HIF-1α) activity in vitro. It acts as a potential antiangiogenic anticancer agent. | | storage | +4°C | | References | [1] E. MARTIN F M Yu chen Lee. YC-1 activation of human soluble guanylyl cyclase has both heme-dependent and heme-independent components[J]. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98 1: 12938-12942. DOI:10.1073/pnas.231486198
[2] HIDENORI KATO. Induction of human endometrial cancer cell senescence through modulation of HIF-1α activity by EGLN1[J]. International Journal of Cancer, 2005, 118 5: 1144-1153. DOI:10.1002/ijc.21488
[3] HYE-LIM KIM. A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent.[J]. International journal of oncology, 2006, 29 1: 255-260.
[4] SHIH-HUANG TAI. Therapeutic window for YC‑1 following glutamate‑induced neuronal damage and transient focal cerebral ischemia.[J]. Molecular medicine reports, 2018: 6490-6496. DOI:10.3892/mmr.2018.8660
[5] YUNG-CHIEH TSAI. The role of heat shock protein 70 in the protective effect of YC-1 on β-amyloid-induced toxicity in differentiated PC12 cells.[J]. PLoS ONE, 2013: e69320. DOI:10.1371/journal.pone.0069320 |
| | YC-1 Preparation Products And Raw materials |
|